Skip to main content
J&J's plaque psoriasis drug wins FDA nod
7/14/2017

Johnson & Johnson unit Janssen Biotech's Tremfya, or guselkumab, has been granted approval by the FDA as a treatment for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Full Story: